Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Tevogen Bio (Nasdaq: TVGN) announced it will host two panel discussions at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2025. The first panel, ‘AI In Biopharma: Next Frontier of Medical Innovation’, will explore how AI technologies can revolutionize drug discovery, accelerate development, and reduce costs. The second panel, ‘Pioneering the Economics of Health: Balancing Access and Outcomes’, will examine healthcare ecosystem interdependencies.
Notable panelists include Microsoft’s Global Chief Medical Officer David Rhew, Rubix Health’s Sean Tunis, Simon-Kucher’s Peter Ehrhardt, and former VA Acting Under Secretary Poonam Alaigh. The event will be held at the Marines’ Memorial Club & Hotel, featuring panel discussions from 2:00 PM to 4:00 PM PST, followed by a reception.
Tevogen Bio (Nasdaq: TVGN) ha annunciato che ospiterà due discussioni di panel alla 43ª Conferenza Annuale sulla Salute J.P. Morgan a San Francisco il 13 gennaio 2025. Il primo panel, ‘AI In Biopharma: La Prossima Frontiera dell’Innovazione Medica’, esplorerà come le tecnologie AI possano rivoluzionare la scoperta di farmaci, accelerare lo sviluppo e ridurre i costi. Il secondo panel, ‘Pionieri dell’Economia della Salute: Bilanciare Accesso e Risultati’, esaminerà le interdipendenze nell’ecosistema sanitario.
I panelisti di spicco includono David Rhew, Chief Medical Officer Globale di Microsoft, Sean Tunis di Rubix Health, Peter Ehrhardt di Simon-Kucher e Poonam Alaigh, ex Sottosegretaria ad interim del VA. L’evento si terrà presso il Marines’ Memorial Club & Hotel, con discussioni di panel dalle 14:00 alle 16:00 PST, seguite da un ricevimento.
Tevogen Bio (Nasdaq: TVGN) anunció que albergará dos paneles de discusión en la 43ª Conferencia Anual de Salud J.P. Morgan en San Francisco el 13 de enero de 2025. El primer panel, ‘AI In Biopharma: La Próxima Frontera de la Innovación Médica’, explorará cómo las tecnologías de IA pueden revolucionar el descubrimiento de fármacos, acelerar el desarrollo y reducir costos. El segundo panel, ‘Pioneros en la Economía de la Salud: Equilibrando Acceso y Resultados’, examinará las interdependencias del ecosistema sanitario.
Los panelistas destacados incluyen a David Rhew, Director Médico Global de Microsoft, Sean Tunis de Rubix Health, Peter Ehrhardt de Simon-Kucher y Poonam Alaigh, ex Subsecretaria interina de VA. El evento se llevará a cabo en el Marines’ Memorial Club & Hotel, con discusiones de panel de 14:00 a 16:00 PST, seguidas de una recepción.
Tevogen Bio (Nasdaq: TVGN)는 2025년 1월 13일 샌프란시스코에서 열리는 제43회 J.P. Morgan Healthcare Conference에서 두 개의 패널 토론을 주최할 것이라고 발표했습니다. 첫 번째 패널, ‘AI In Biopharma: 의료 혁신의 다음 경계’,는 AI 기술이 약물 발견을 혁신하고 개발을 가속화하며 비용을 절감할 수 있는 방법을 탐구합니다. 두 번째 패널, ‘건강 경제학의 선도: 접근성과 결과의 균형’,은 의료 생태계의 상호 의존성을 살펴봅니다.
주요 패널리스트로는 Microsoft의 글로벌 수석 의학 책임자 David Rhew, Rubix Health의 Sean Tunis, Simon-Kucher의 Peter Ehrhardt, 그리고 전 VA 차관 보조 Poonam Alaigh가 있습니다. 이 행사는 Marines’ Memorial Club & Hotel에서 열리며, 패널 토론은 오후 2시부터 4시까지 PST까지 진행되며, 이어서 리셉션이 있을 예정입니다.
Tevogen Bio (Nasdaq: TVGN) a annoncé qu’elle organisera deux tables rondes lors de la 43e conférence annuelle sur la santé J.P. Morgan à San Francisco le 13 janvier 2025. La première table ronde, ‘AI In Biopharma: La Prochaine Frontière de l’Innovation Médicale’, explorera comment les technologies d’IA peuvent révolutionner la découverte de médicaments, accélérer le développement et réduire les coûts. La seconde table ronde, ‘Pionniers de l’Économie de la Santé: Équilibrer Accès et Résultats’, examinera les interdépendances de l’écosystème de la santé.
Parmi les panelistes notables figurent David Rhew, médecin-chef mondial de Microsoft, Sean Tunis de Rubix Health, Peter Ehrhardt de Simon-Kucher et Poonam Alaigh, ancienne sous-secrétaire par intérim du VA. L’événement se déroulera au Marines’ Memorial Club & Hotel, avec des discussions de panel de 14h00 à 16h00 PST, suivies d’une réception.
Tevogen Bio (Nasdaq: TVGN) gab bekannt, dass am 13. Januar 2025 in San Francisco zwei Podiumsdiskussionen auf der 43. jährlichen J.P. Morgan Healthcare Conference stattfinden werden. Das erste Panel, ‘AI In Biopharma: Die nächste Grenze der medizinischen Innovation’, wird untersuchen, wie KI-Technologien die Medikamentenentdeckung revolutionieren, die Entwicklung beschleunigen und die Kosten senken können. Das zweite Panel, ‘Pioniere der Gesundheitsökonomie: Balance zwischen Zugang und Ergebnissen’, wird die Interdependenzen im Gesundheitsökosystem analysieren.
Zu den bemerkenswerten Panelisten gehören David Rhew, Global Chief Medical Officer von Microsoft, Sean Tunis von Rubix Health, Peter Ehrhardt von Simon-Kucher und die ehemalige VA-Stellvertreterin Poonam Alaigh. Die Veranstaltung findet im Marines’ Memorial Club & Hotel statt und umfasst Diskussionsrunden von 14:00 bis 16:00 PST, gefolgt von einem Empfang.
Positive
- Participation in major healthcare investment symposium enhances company visibility
- Strategic focus on AI implementation in biopharma operations
- High-profile panel participants from Microsoft, VA, and other major institutions
- The JPM Healthcare Conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
- Pioneering the Economics of Health to examine the interdependencies of the healthcare ecosystem which are often overlooked when only considering a singular silo of it.
- AI In Biopharma to highlight how AI-driven technologies can revolutionize drug discovery, accelerate development timelines, enhance patient accessibility, foster quicker innovation, and significantly reduce operating costs.
- Panelists to include David Rhew (Global Chief Medical Officer and VP of Healthcare, Microsoft), Sean Tunis (Principal, Rubix Health), Peter Ehrhardt (Senior Partner, Simon-Kucher), and Poonam Alaigh (Former Acting Under Secretary for Health, U.S. Department of Veterans Affairs).
WARREN, N.J., Dec. 26, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), will host panel discussions at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Event Details
Date:
Monday, January 13, 2025
Location:
Marines’ Memorial Club & Hotel, 609 Sutter St., San Francisco, CA 94102
Time (PST):
2:00 PM – 2:30 PM – AI in Biopharma: Next Frontier of Medical Innovation
Panelists:
Dr. David Rhew – Global Chief Medical Officer and VP of Healthcare, Microsoft (Nasdaq: MSFT)
Dr. Sean Tunis – Principal, Rubix Health
Mittul Mehta – Chief Information Officer and Head of Tevogen.AI, Tevogen Bio
2:30 pm – 3:15 pm – Afternoon Coffee Break
3:15 PM – 4:00 PM – Pioneering the Economics of Health: Balancing Access and Outcomes
Victor Sordillo – MD, Risk Advisory Services, Verita CSG, Inc; Member, Board of Directors, Tevogen Bio
Peter Ehrhardt – Senior Partner at Simon-Kucher & Partners
Dr. Poonam Alaigh – Former Acting Under Secretary for Health, U.S. Department of Veterans Affairs; Former Commissioner, New Jersey Department of Health
Dr. Sean Tunis – Principal, Rubix Health; Senior Fellow, Tufts Center for Evaluation of Value and Risk in Health; Venture Mentor, Johns Hopkins Tech Ventures
Dr. Ryan Saadi – Founder and CEO, Tevogen Bio
4:00 PM – 6:00 PM – Reception and Cocktails
For inquiries regarding additional event details, please contact communications@tevogen.com.
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
When and where will Tevogen Bio (TVGN) host its panels at the JP Morgan Healthcare Conference 2025?
Tevogen Bio will host its panels on Monday, January 13, 2025, at the Marines’ Memorial Club & Hotel in San Francisco, California.
What are the main topics of Tevogen Bio’s (TVGN) panel discussions at JPM 2025?
The two main topics are ‘AI In Biopharma: Next Frontier of Medical Innovation’ and ‘Pioneering the Economics of Health: Balancing Access and Outcomes’.
Who are the key speakers at Tevogen Bio’s (TVGN) JPM 2025 panels?
Key speakers include David Rhew (Microsoft), Sean Tunis (Rubix Health), Peter Ehrhardt (Simon-Kucher), and Poonam Alaigh (Former VA Under Secretary).
What AI benefits will be discussed at Tevogen Bio’s (TVGN) JPM panel?
The panel will discuss how AI can revolutionize drug discovery, accelerate development timelines, enhance patient accessibility, foster innovation, and reduce operating costs.
